secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovAccess Global Inc. (—)
CIK:        0001039466
Form:       8-K
Filed at:   2024-05-03T23:59:59+00:00
Accession:  0001185185-24-000455
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 2.03, 3.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovAccess enters $26.5K note with AJB Capital and licenses IDH1 biomarker from Cedars-Sinai
--------------------------------------------------------------------------------

- Issued $26,500 promissory note to AJB Capital Investments, 12% interest, 10% OID, due Oct 26, 2024.
- Issued 2.5M unregistered common shares as commitment fee; granted security interest in all assets including StemVax equity.
- Default triggers 18% interest, conversion at discount, and 2x principal penalty.
- Obtained exclusive IDH1 biomarker license from Cedars-Sinai for predicting vaccine response in glioblastoma.
- Intends to use IDH1 as companion diagnostic for TLR-AD1, an FDA Orphan Drug designated candidate for CNS cancers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1039466/000118518524000455/0001185185-24-000455-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1039466/000118518524000455/novaccess20240501_8k.htm
  HTML page:      https://secwatch.observer/filing/0001185185-24-000455

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer